Prescribing InformationPatient Tool Kit
Logo
About SEM-P?Mechanism of ActionProven ResultVideo Library
Prescribing InformationPatient Tool Kit
Logo
About SEM-P?Mechanism of ActionProven ResultVideo Library

GLP-1 Receptor Activation

Semaglutide selectively activates the glucagon-like peptide-1 (GLP-1) receptor, a key incretin pathway involved in glucose and appetite regulation.

  • Mimics endogenous GLP-1 activity
  • Enhances glucose-dependent insulin secretion
  • Suppresses inappropriate glucagon release
  • Regulates appetite and gastric emptying

Integrated Effects on Key Systems

Tirzee Pen
Semaglutide improves pancreatic hormone balance in a glucose-dependent manner.
  • Increases insulin secretion when blood glucose is elevated
  • Suppresses excess glucagon secretion
  • Improves β-cell responsiveness
  • Reduces fasting and post-prandial plasma glucose levels

Integrated Clinical Effect

By activating the GLP-1 receptor across pancreatic, central, gastrointestinal, and metabolic pathways, SEM-P® addresses multiple components of dysglycaemia and weight dysregulation in type 2 diabetes.

Drug Delivery & Administration

SEM-P is available for subcutaneous administration using:

  • Pre-filled injection pens
  • Injection vials
  • Once-weekly dosing
  • Delivery method supports sustained systemic exposure
  • Designed to support dosing flexibility and clinical practice needs
Image